Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.61
+0.01 (+1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-21.9M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$844M
P/E
N/A
•EV/EBITDA
52.8x
↑ROE
-22.2%
↓Gross Margin
47.3%
↓Debt/Equity
0.99
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+53.3%
FCF CAGR
—
FCF margin
-9.7%
FCF / Net income
0.38x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $268.8M · net income $-68.1M · FCF $-26.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $268.8M | $268.8M | $99.4M | $88.1M | $74.6M |
| Net Income | $-68.1M | $-68.1M | $-28.0M | $-25.5M | $-42.5M |
| EBITDA | $12.3M | $12.3M | $17.7M | $17.0M | $-10.0M |
| EPS | -0.09 | -0.09 | -0.16 | -0.19 | -0.33 |
| Gross Margin | 47.3% | 47.3% | 51.1% | 50.0% | 41.4% |
| Operating Margin | 3.8% | 3.8% | 18.2% | 12.0% | -9.3% |
| Net Margin | -25.3% | -25.3% | -28.2% | -29.0% | -56.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.99 | 0.99 | 1.62 | -5.04 | 40.53 |
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-26.1M | $-26.1M | $-21.9M | $-7.0M | $-23.6M |
| Returns | |||||
| ROE | -22.2% | -22.2% | -50.4% | 159.2% | -1233.9% |
| Valuation | |||||
| EV/EBITDA | 52.82 | 52.82 | 8.09 | 6.50 | — |
| P/B | 1.46 | 1.46 | 2.60 | — | 10.05 |
| Growth & Yield | |||||
| Revenue Growth | 170.4% | 170.4% | 12.8% | 18.1% | — |
| EPS Growth | 43.8% | 43.8% | 15.8% | 42.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+28.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.09
Residual
+28.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.